Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Valsartan and the kidney: Review of preclinical and clinical data
Autore:
Ruilope, LM;
Indirizzi:
Hosp 12 Octubre, Serv Nefrol, E-28041 Madrid, Spain Hosp 12 Octubre Madrid Spain E-28041 Serv Nefrol, E-28041 Madrid, Spain
Titolo Testata:
ADVANCES IN THERAPY
fascicolo: 2, volume: 18, anno: 2001,
pagine: 57 - 66
SICI:
0741-238X(200103/04)18:2<57:VATKRO>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANGIOTENSIN-CONVERTING-ENZYME; II RECEPTOR BLOCKADE; SPONTANEOUSLY HYPERTENSIVE RATS; DIABETIC NEPHROPATHY; RENAL-INSUFFICIENCY; ANTIHYPERTENSIVE AGENTS; PHARMACOLOGICAL PROFILE; GLOMERULAR INJURY; HEALTHY-SUBJECTS; ACE-INHIBITORS;
Keywords:
ACE inhibitors; angiotensin; hypertension; renal function; renin-angiotensin system;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
68
Recensione:
Indirizzi per estratti:
Indirizzo: Ruilope, LM Hosp 12 Octubre, Serv Nefrol, E-28041 Madrid, Spain Hosp 12 Octubre Madrid Spain E-28041 , E-28041 Madrid, Spain
Citazione:
L.M. Ruilope, "Valsartan and the kidney: Review of preclinical and clinical data", ADV THER, 18(2), 2001, pp. 57-66

Abstract

In both diabetic and nondiabetic renal disease, reducing blood pressure with antihypertensive therapy has beneficial effects on renal function. The key role of the renin-angiotensin system in blood pressure and volume homeostasis has long been established, but its importance for the overall normal functioning of the kidney itself is also increasingly being recognized. Angiotensin-converting enzyme (ACE) inhibitors, widely and successfully used in the treatment of hypertension, may also provide renal protection independent of blood pressure reduction; however, their relatively nonspecific modeof action in blocking an early metabolic step entails major clinical disadvantages, such as accumulation of bradykinin and substance P, that may cause the characteristic ACE-inhibitor side effects of persistent dry cough and, more rarely, angioneurotic edema. Angiotensin II antagonists or receptor blockers, a new class of antihypertensive agent, selectively antagonize theAT, receptor subtype and, because of greater specificity, do not: give rise to the side effects associated with ACE inhibitors. More important, thesenew drugs may have mechanistic advantages over other antihypertensives, including ACE inhibitors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 19:23:24